title: Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus.
abstract: Dengue disease is an increasing global health problem that threatens one-third of the world's population. Despite decades of efforts, no licensed vaccine against dengue is available. With the aim to develop an affordable vaccine that could be used in young populations living in tropical areas, we evaluated a new strategy based on the expression of a minimal dengue antigen by a vector derived from pediatric live-attenuated Schwarz measles vaccine (MV). As a proof-of-concept, we inserted into the MV vector a sequence encoding a minimal combined dengue antigen composed of the envelope domain III (EDIII) fused to the ectodomain of the membrane protein (ectoM) from DV serotype-1. Immunization of mice susceptible to MV resulted in a long-term production of DV1 serotype-specific neutralizing antibodies. The presence of ectoM was critical to the immunogenicity of inserted EDIII. The adjuvant capacity of ectoM correlated with its ability to promote the maturation of dendritic cells and the secretion of proinflammatory and antiviral cytokines and chemokines involved in adaptive immunity. The protective efficacy of this vaccine should be studied in non-human primates. A combined measles-dengue vaccine might provide a one-shot approach to immunize children against both diseases where they co-exist.
authors.affiliation: Viral Genomics and Vaccination Laboratory, Institut Pasteur, CNRS-URA3015, Paris, France.
authors.forename: Samantha
authors.initials: S
authors.lastname: Brandler
authors.forename: Marianne
authors.initials: M
authors.lastname: Lucas-Hourani
authors.forename: Arnaud
authors.initials: A
authors.lastname: Moris
authors.forename: Marie-Pascale
authors.initials: MP
authors.lastname: Frenkiel
authors.forename: Chantal
authors.initials: C
authors.lastname: Combredet
authors.forename: Michèle
authors.initials: M
authors.lastname: Février
authors.forename: Hugues
authors.initials: H
authors.lastname: Bedouelle
authors.forename: Olivier
authors.initials: O
authors.lastname: Schwartz
authors.forename: Philippe
authors.initials: P
authors.lastname: Desprès
authors.forename: Frédéric
authors.initials: F
authors.lastname: Tangy
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000096:biosynthesis* / Q000276:immunology; D000914:Antibodies, Viral / Q000096:biosynthesis* / Q000276:immunology; D000918:Antibody Specificity; D000956:Antigens, Viral / Q000235:genetics / Q000276:immunology*; D002470:Cell Survival; D002522:Chlorocebus aethiops; D016207:Cytokines / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology; D003715:Dengue / Q000276:immunology / Q000517:prevention & control; D003716:Dengue Virus / Q000235:genetics / Q000276:immunology*; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D006801:Humans; D007156:Immunologic Memory; D008458:Measles Vaccine / Q000235:genetics / Q000276:immunology*; D051379:Mice; D014613:Vaccines, Attenuated / Q000276:immunology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology; D014709:Vero Cells; D014779:Virus Replication
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D000956:Antigens, Viral; D016207:Cytokines; D008458:Measles Vaccine; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic